Pliant Therapeutics, Inc. (PLRX)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGS
1.14 USD
+0.02
(1.786%)
⇧
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 4:43 a.m. EDT
This biotech stock is in a severe structural decline with no immediate catalyst to reverse the trend. The company has lost over 94% of its value over the last five years, with four consecutive years of negative annual returns, culminating in an 88% drop last year. Fundamentally, the picture is dire: the company is burning through cash with negative free cash flow, negative operating cash flow, and negative returns on both assets and equity. The balance sheet, while currently showing a high current ratio due to cash reserves, is propping up a business that cannot generate its own capital. With no dividends paid and a negative forward P/E, there is no income floor and no earnings support. The options market confirms this pessimism, with traders aggressively buying puts to hedge against further losses. Despite a target price suggesting potential recovery, the lack of revenue growth and the relentless multi-year price collapse indicate that the market has correctly identified a deteriorating business. This is a speculative vehicle for high-risk capital, not a viable investment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.027014 |
| MSTL | 0.030582 |
| AutoETS | 0.034359 |
| AutoARIMA | 0.084575 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 45% |
| H-stat | 2.63 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.367 |
| Excess Kurtosis | -0.51 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 17.427 |
| Market Cap | 70,589,080 |
| Forward P/E | -1.41 |
| Beta | 1.22 |
| Website | https://pliantrx.com |
As of July 11, 2026, 4:43 a.m. EDT: Speculators are overwhelmingly positioning for downside protection rather than upside participation. Put volume and open interest significantly exceed call volume across all expirations, with the $1.0 strike acting as a heavy anchor for both sides. While there is notable open interest in out-of-the-money calls at the $1.50 and $2.50 strikes, the massive concentration of put open interest suggests a 'bear put spread' or hedging strategy is dominant, indicating the market expects further weakness or a floor test near current levels.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.22758621 |
| Address1 | 331 Oyster Point Boulevard |
| All Time High | 43.92 |
| All Time Low | 1.09 |
| Ask | 1.42 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 535,340 |
| Average Daily Volume3 Month | 497,293 |
| Average Volume | 497,293 |
| Average Volume10Days | 535,340 |
| Beta | 1.217 |
| Bid | 0.828 |
| Bid Size | 2 |
| Book Value | 2.688 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.14 |
| Current Ratio | 16.887 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 1.175 |
| Day Low | 1.1096 |
| Debt To Equity | 17.427 |
| Display Name | Pliant Therapeutics |
| Earnings Timestamp | 1,778,529,600 |
| Earnings Timestamp End | 1,786,046,400 |
| Earnings Timestamp Start | 1,786,046,400 |
| Ebitda | -111,398,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.647 |
| Enterprise Value | -72,055,808 |
| Eps Current Year | -1.40974 |
| Eps Forward | -0.80769 |
| Eps Trailing Twelve Months | -1.83 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.1769 |
| Fifty Day Average Change | -0.036900043 |
| Fifty Day Average Change Percent | -0.031353593 |
| Fifty Two Week Change Percent | -22.758621 |
| Fifty Two Week High | 1.95 |
| Fifty Two Week High Change | -0.81000006 |
| Fifty Two Week High Change Percent | -0.41538465 |
| Fifty Two Week Low | 1.09 |
| Fifty Two Week Low Change | 0.049999952 |
| Fifty Two Week Low Change Percent | 0.045871515 |
| Fifty Two Week Range | 1.09 - 1.95 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,591,191,000,000 |
| Float Shares | 56,608,929 |
| Forward Eps | -0.80769 |
| Forward P E | -1.4114325 |
| Free Cashflow | -65,969,752 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 49 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02226 |
| Held Percent Institutions | 0.82056 |
| Implied Shares Outstanding | 61,920,249 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-06-03 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. |
| Long Name | Pliant Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 70,589,080 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_325980525 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -113,218,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 69,969,881 |
| Number Of Analyst Opinions | 2 |
| Open | 1.12 |
| Operating Cashflow | -98,701,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 650 481 6770 |
| Previous Close | 1.12 |
| Price Eps Current Year | -0.80865973 |
| Price Hint | 4 |
| Price To Book | 0.42410713 |
| Profit Margins | 0.0 |
| Quick Ratio | 16.585 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.02 |
| Regular Market Change Percent | 1.78571 |
| Regular Market Day High | 1.175 |
| Regular Market Day Low | 1.1096 |
| Regular Market Day Range | 1.1096 - 1.175 |
| Regular Market Open | 1.12 |
| Regular Market Previous Close | 1.12 |
| Regular Market Price | 1.14 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 1,219,319 |
| Return On Assets | -0.25785 |
| Return On Equity | -0.53616 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 61,920,249 |
| Shares Percent Shares Out | 0.0417 |
| Shares Short | 2,582,648 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 3,436,210 |
| Short Name | Pliant Therapeutics, Inc. |
| Short Percent Of Float | 0.0427 |
| Short Ratio | 5.64 |
| Source Interval | 15 |
| State | CA |
| Symbol | PLRX |
| Target High Price | 3.0 |
| Target Low Price | 2.0 |
| Target Mean Price | 2.5 |
| Target Median Price | 2.5 |
| Total Cash | 170,892,000 |
| Total Cash Per Share | 2.781 |
| Total Debt | 28,784,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.83 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.3272 |
| Two Hundred Day Average Change | -0.18720007 |
| Two Hundred Day Average Change Percent | -0.14104888 |
| Type Disp | Equity |
| Volume | 1,219,319 |
| Website | https://pliantrx.com |
| Zip | 94,080 |